Vectura’s $62.7m inhalation centre granted planning permission

Published: 28-Sep-2022
Drug Delivery

The state-of-the-art building is set to be completed in 2025 and will enable Vectura to expand its operations

Vectura, which specialises in inhaled drug development solutions, has announced planning permission for a new 10,000 square metre facility in Bristol & Bath Science Park, which will become the company’s ‘Inhalation Centre of Excellence’.

The state-of-the-art £58 million building is set to be completed in 2025 and will enable Vectura to expand its operations, while providing new career opportunities for research and development scientists and engineers in pharmaceutical and device development, as well as manufacturing and laboratory services.

In constructing the new Inhalation Centre of Excellence, Vectura aims to create an optimal environment for innovation to support the development of important new inhaled treatments and wellness products. The company is also targeting the goal of achieving an ‘Excellent’ rating for the building with sustainability assessors BREEAM.

For nearly 25 years, Vectura has been providing a combination of formulation science, device technology and pharmaceutical development expertise, helping our partners and licensees develop products which are used by 10 million patients worldwide

Michael Austwick, Chief Executive Officer, Vectura, said: “We are delighted that our plans to build a world-leading science facility have been approved. The new-build will enable our already successful pharmaceutical company to continue and expand upon its vital work, providing innovative inhalation and other advanced drug delivery solutions that have the potential to improve the lives of patients around the world.”

Austwick continued: “For nearly 25 years, Vectura has been providing a combination of formulation science, device technology and pharmaceutical development expertise, helping our partners and licensees develop products which are used by 10 million patients worldwide. This new facility will help us to build on this successful track record, increasing workspace capacity and attracting talent to the area.”

Vectura currently has UK facilities in Chippenham and Cambridge, and helps partners to bring their medicines to market by drawing upon its specialist DPI, pMDI and nebuliser capabilities. Its combination of formulation science, device technology and inhaled development expertise has contributed to the success of 13 medicines.

  • Companies:
  • Vectura Group
See more

You may also like

Drug Delivery

Optimising dry powder inhaler programmes through formulation

Read more
The use of dry powder formulations originally focused on respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) because pulmonary administration of the active pharmaceutical ingredient (API) provides direct and rapid action. However, direct delivery to the lung is also a quick and efficient way of administering non-respiratory drugs systemically without have to wait for them to be absorbed through the gut

Trending Articles

  1. Sanofi invests €40m into biopharmaceutical manufacturing at its Lyon Gerland site The pharma giant has expanded its French monoclonal antibody production capabilities, while also dedicating €25m to the development of a second-gen polyclonal antibody
  2. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms
  3. Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles
  4. Challenges and development perspectives of primary packaging for parenteral drugs When talking about parenteral drugs, we usually refer to the administration of drugs by injection through the integument or directly into the circulation, says Andrea Sentimenti, Marketing & Innovation Director at Bormioli Pharma. The parenteral route – it could be intradermal, subcutaneous, intramuscular or intravenous – indeed allows a rapid effect, the administration of orally inactivated drugs, rapid intervention in emergencies, and the administration of nutritional solutions to patients who cannot feed themselves normally
  5. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Drug Delivery

Optimising dry powder inhaler programmes through formulation

The use of dry powder formulations originally focused on respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) because pulmonary administration of the active pharmaceutical ingredient (API) provides direct and rapid action. However, direct delivery to the lung is also a quick and efficient way of administering non-respiratory drugs systemically without have to wait for them to be absorbed through the gut
Ingredients

Accelerating excipient development for inhalable dosage forms with QbD

Whether they are simply giving an oral dose the bulk it needs to permit handling and swallowing or performing more complex functions that enable successful delivery and product performance, excipients are critical components of all drug formulations, explains Iain Davidson, Senior Manager, Pharmaceutical Development, Vectura
Regulatory

Vectura earns $11m milestone with Hikma generic launch

The launch of the product follows approval by the US FDA
Regulatory

Status update on ANDA for generic Advair Diskus (VR315 [US])

Vectura Group, an industry leading inhalation CDMO, confirms the announcement made by its partner Hikma Pharmaceuticals
Drug Delivery

Hikma announces agreement with Vectura to develop generic salmeterol for the US market

Hikma is a fast-growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products
Drug Delivery

Vectura and Propeller Health link up to develop digitally-connected inhalers for chronic respiratory diseases

The two firms are also discussing additional connected strategies for other proprietary respiratory devices in Vectura’s pipeline
Regulatory

Recipharm provides access to dossier for Asmasal Clickhaler Chinese market approval

Regulatory submission will be led by Vectura’s new strategic joint venture , Tianjin Kinnovata; collaboration will see Recipharm manufacturing finished product for Kinnovata and the Chinese market
Subscribe now